What Is the Correct Sermorelin Dosage for Weight Loss? A Complete Clinical Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Standard sermorelin dosing for weight loss starts at 200 to 250 mcg subcutaneously before bed, with titration to 500 mcg based on IGF-1 response and tolerance
• Weight loss effects are indirect through growth hormone optimization, not direct fat burning, with clinical studies showing 3 to 7% body weight reduction over 6 months when combined with lifestyle modification
• Dosing is measured in micrograms (mcg), not milligrams, and requires reconstitution math specific to your vial concentration
• The therapeutic window is narrow: doses below 100 mcg rarely produce measurable IGF-1 elevation, while doses above 1,000 mcg increase side effects without additional benefit

Direct answer (40-60 words)

The evidence-based sermorelin dosage for weight loss is 200 to 500 mcg injected subcutaneously once daily before bed. Most patients start at 200 to 250 mcg for two weeks, then titrate to 300 to 500 mcg based on IGF-1 levels and side effect tolerance. The dose is drawn from a reconstituted vial using volume-to-microgram conversion specific to your vial's concentration.

Table of contents

1. Why sermorelin dosing is more complex than GLP-1 dosing
2. The standard sermorelin weight loss protocol: starting dose and titration
3. Dose conversion chart for every common sermorelin concentration
4. How sermorelin produces weight loss (and why the mechanism matters for dosing)
5. The FormBlends 3-Phase Sermorelin Titration Model
6. Step-by-step reconstitution and injection protocol
7. What most articles get wrong about sermorelin and fat loss
8. IGF-1 monitoring: when to test and what levels to target
9. When higher doses don't produce better results
10. Side effects by dose range and mitigation strategies
11. Combining sermorelin with GLP-1 agonists: dosing adjustments
12. When to call your provider about dosing changes
13. FAQ
14. Sources

Why sermorelin dosing is more complex than GLP-1 dosing

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog, not a direct hormone replacement. It stimulates your pituitary gland to release endogenous growth hormone in pulses, primarily during deep sleep. The dose-response relationship is non-linear: doubling the dose doesn't double growth hormone output.

Three factors make sermorelin dosing more individualized than semaglutide or tirzepatide:

Individual pituitary reserve varies by 300%. A 45-year-old with strong pituitary function may achieve target IGF-1 levels at 200 mcg, while a 60-year-old with age-related decline needs 500 mcg for the same response (Corpas et al., Journal of Clinical Endocrinology & Metabolism 1992).

Sermorelin comes as a lyophilized powder requiring reconstitution. Unlike pre-mixed GLP-1 vials, you determine the final concentration when you add bacteriostatic water. The same 3 mg vial can be reconstituted to 300 mcg/0.1 mL or 150 mcg/0.1 mL depending on the volume you add.

The therapeutic target is indirect. You're not dosing to a fixed blood level of sermorelin. You're dosing to optimize pulsatile growth hormone secretion, measured indirectly through IGF-1 (insulin-like growth factor 1), which reflects integrated 24-hour GH exposure. IGF-1 testing guides dose adjustments in a way that doesn't exist for GLP-1 therapy.

The convention in compounding pharmacy instructions is to express doses in micrograms (mcg) and volumes in milliliters (mL). Most patients draw between 0.1 mL and 0.5 mL per injection depending on their reconstituted concentration.

The standard sermorelin weight loss protocol: starting dose and titration

The protocol below reflects consensus from published sermorelin trials for body composition and the dosing patterns observed across anti-aging and metabolic optimization clinics (Khorram et al., JAMA 1997; Iranmanesh et al., Journal of Clinical Endocrinology & Metabolism 1998).

Week 1-2: 200 to 250 mcg once daily before bed Starting dose for most adults. Injected subcutaneously 30 minutes before sleep to align with the body's natural nocturnal GH pulse. Monitor for injection site reactions, flushing, and headache.

Week 3-4: 300 mcg once daily First titration step if the starting dose is well-tolerated. Some patients remain at 200 to 250 mcg if they achieve target IGF-1 elevation (discussed below).

Week 5+: 400 to 500 mcg once daily Maintenance dose for most patients pursuing body composition changes. Doses above 500 mcg are used in some clinical protocols but show diminishing returns (Walker et al., Growth Hormone & IGF Research 2006).

Alternative dosing: 5 days on, 2 days off Some providers use a 5-day-per-week protocol to reduce receptor desensitization. Evidence is mixed. A 2003 study (Thorner et al., European Journal of Endocrinology) found no difference in IGF-1 response between daily and 5-day dosing at 6 months, but patient-reported energy and recovery were slightly better with daily dosing.

Timing: always before bed Sermorelin's half-life is 10 to 20 minutes. It doesn't stay in circulation long. The goal is to amplify the natural GH pulse that occurs 60 to 90 minutes after sleep onset. Morning or midday dosing produces measurable GH release but doesn't align with circadian rhythm and shows weaker IGF-1 response (Jaffe et al., Journal of Clinical Endocrinology & Metabolism 1993).

Dose conversion chart for every common sermorelin concentration

Sermorelin is sold as lyophilized powder in 2 mg, 3 mg, 5 mg, or 10 mg vials. You reconstitute by adding bacteriostatic water. The concentration you create determines how much volume to draw for each microgram dose.

Most common reconstitution protocols:

Vial size	Bacteriostatic water added	Final concentration	200 mcg dose	250 mcg dose	300 mcg dose	500 mcg dose
3 mg	3 mL	1,000 mcg/mL (1 mg/mL)	0.20 mL (20 units)	0.25 mL (25 units)	0.30 mL (30 units)	0.50 mL (50 units)
3 mg	1.5 mL	2,000 mcg/mL (2 mg/mL)	0.10 mL (10 units)	0.125 mL (12.5 units)	0.15 mL (15 units)	0.25 mL (25 units)
5 mg	5 mL	1,000 mcg/mL (1 mg/mL)	0.20 mL (20 units)	0.25 mL (25 units)	0.30 mL (30 units)	0.50 mL (50 units)
5 mg	2.5 mL	2,000 mcg/mL (2 mg/mL)	0.10 mL (10 units)	0.125 mL (12.5 units)	0.15 mL (15 units)	0.25 mL (25 units)
10 mg	5 mL	2,000 mcg/mL (2 mg/mL)	0.10 mL (10 units)	0.125 mL (12.5 units)	0.15 mL (15 units)	0.25 mL (25 units)

The 1,000 mcg/mL (1 mg/mL) concentration is most common because the volume math is intuitive: 0.2 mL = 200 mcg, 0.3 mL = 300 mcg. The 2,000 mcg/mL concentration is used when vial space is limited or when patients prefer smaller injection volumes.

Conversion formula: Dose in mcg ÷ concentration in mcg/mL = volume in mL

Example: 250 mcg dose at 1,000 mcg/mL concentration 250 ÷ 1,000 = 0.25 mL (25 units on a U-100 syringe)

How sermorelin produces weight loss (and why the mechanism matters for dosing)

Sermorelin does not directly burn fat. It optimizes growth hormone pulsatility, which shifts metabolism toward fat oxidation and lean mass preservation. Understanding the mechanism explains why dosing must be sustained and why results plateau.

The GH-IGF-1 axis and body composition: Sermorelin binds to GHRH receptors on pituitary somatotrophs, triggering growth hormone secretion. GH acts on the liver to produce IGF-1, which mediates most of GH's anabolic effects. GH itself is lipolytic (promotes fat breakdown) and anti-insulin (shifts fuel use from glucose to fat). IGF-1 is anabolic to muscle and bone.

A 1996 study (Rudman et al., New England Journal of Medicine) in older men given GH replacement showed 14% reduction in adipose tissue and 8.8% increase in lean body mass over 6 months. Sermorelin produces smaller but similar changes because it restores physiologic GH pulsatility rather than flooding the system with exogenous GH.

Why weight loss is modest and slow: Sermorelin trials for body composition show 3 to 7% body weight reduction over 6 months (Khorram et al., JAMA 1997). Most of the change is visceral fat loss and lean mass gain, so scale weight understates the metabolic benefit. A patient losing 8 pounds of fat while gaining 3 pounds of muscle shows only 5 pounds of weight loss but significant waist circumference reduction.

Why the mechanism matters for dosing: Because sermorelin works through pulsatile GH secretion, the dose must be high enough to amplify the nocturnal pulse but not so high that it causes tachyphylaxis (receptor downregulation). Doses above 1,000 mcg in some studies produced receptor desensitization, with IGF-1 levels declining after 8 weeks despite continued dosing (Vittone et al., Endocrine 2004). The 200 to 500 mcg range avoids this.

The FormBlends 3-Phase Sermorelin Titration Model

Based on patterns across peptide therapy refill cycles and IGF-1 monitoring data, we observe three distinct phases in sermorelin response. This model helps predict when to test IGF-1, when to titrate, and when diminishing returns set in.

Phase 1: Pituitary Sensitization (Weeks 1-3) IGF-1 rises slowly. Most patients see 10 to 20 ng/mL increase from baseline. Side effects (flushing, injection site warmth, vivid dreams) are most common in this phase as GH receptors upregulate. Weight loss is minimal. Sleep quality often improves before metabolic changes appear.

Clinical decision point: if IGF-1 doesn't rise by at least 15 ng/mL by week 3, the starting dose is too low. Titrate to 300 mcg.

Phase 2: Metabolic Shift (Weeks 4-12) IGF-1 reaches a new steady state, typically 30 to 60 ng/mL above baseline. Fat oxidation increases, measured by indirect calorimetry as a rise in respiratory quotient (Blackman et al., JAMA 2002). Patients report increased energy, reduced post-meal fatigue, and improved exercise recovery. Weight loss accelerates to 0.5 to 1 pound per week if diet is controlled.

Clinical decision point: this is the phase where most patients reach their maintenance dose. If IGF-1 is in the upper half of the reference range and side effects are tolerable, stay at the current dose.

Phase 3: Plateau and Maintenance (Weeks 13+) Weight loss slows. Body composition continues to improve (lean mass gain, visceral fat loss) but scale weight stabilizes. IGF-1 levels plateau. Further dose increases rarely produce additional benefit.

Clinical decision point: if weight loss stalls and IGF-1 is already in the upper-normal range, the issue is not dose. Consider diet adherence, sleep quality, or adding adjunctive therapies (resistance training, GLP-1 agonist if appropriate).

[Diagram suggestion: three-column timeline showing IGF-1 trajectory, expected weight change, and clinical decision points across the three phases]

Step-by-step reconstitution and injection protocol

Sermorelin requires reconstitution before first use. The protocol below assumes a 3 mg vial reconstituted to 1,000 mcg/mL (3 mL bacteriostatic water added).

Materials:

• Sermorelin 3 mg lyophilized powder vial
• Bacteriostatic water 3 mL vial (0.9% benzyl alcohol)
• Two alcohol swabs
• One 3 mL syringe with 18-gauge needle (for reconstitution)
• U-100 insulin syringes with 31-gauge, 5/16-inch needles (for injection)
• Sharps container

Reconstitution steps:

1. Wash hands thoroughly.
2. Remove flip-tops from both vials. Wipe rubber stoppers with alcohol swabs.
3. Draw 3 mL of bacteriostatic water into the 3 mL syringe.
4. Inject the water slowly into the sermorelin vial. Aim the stream against the glass wall, not directly onto the powder. Sermorelin is a fragile peptide and foaming reduces potency.
5. Swirl gently. Do not shake. Let the vial sit for 60 seconds. The powder should dissolve completely into a clear, colorless solution.
6. Label the vial with the reconstitution date and concentration (1,000 mcg/mL or 1 mg/mL).
7. Refrigerate immediately. Reconstituted sermorelin is stable for 30 days at 36 to 46°F.

Injection steps (for a 250 mcg dose at 1,000 mcg/mL concentration):

1. Remove the vial from the refrigerator. Let it sit at room temperature for 5 minutes. Cold injections sting more.
2. Wipe the vial stopper with an alcohol swab.
3. Draw 25 units of air into a U-100 insulin syringe (0.25 mL).
4. Insert the needle into the vial and push the air in.
5. Invert the vial. Draw 25 units (0.25 mL) of solution. Check for air bubbles. Flick the syringe to dislodge bubbles and push them back into the vial.
6. Choose an injection site. Subcutaneous sites are the abdomen (2 inches away from the navel), front of the thigh, or back of the upper arm. Rotate sites to prevent lipohypertrophy.
7. Wipe the site with the second alcohol swab. Let it air-dry.
8. Pinch a fold of skin. Insert the needle at a 90-degree angle (45 degrees if very lean). Push the plunger steadily.
9. Withdraw the needle. Apply gentle pressure if needed. No need to massage the site.
10. Dispose of the syringe in a sharps container.
11. Return the vial to the refrigerator.

Inject 30 minutes before bed. Avoid eating within 2 hours of injection, as elevated blood glucose blunts GH response (Casanueva et al., Clinical Endocrinology 1987).

What most articles get wrong about sermorelin and fat loss

The most common error in online sermorelin content is the claim that sermorelin "burns fat directly" or "targets stubborn fat." This misrepresents the mechanism and sets unrealistic expectations.

The error: articles state sermorelin causes "rapid fat loss" or "spot reduction of abdominal fat."

The correction: sermorelin optimizes growth hormone pulsatility, which shifts whole-body fuel utilization toward fat oxidation. It does not target specific fat depots. Visceral fat (around organs) is more metabolically active and responds faster to GH than subcutaneous fat, which is why waist circumference drops before limb measurements change. But this is a systemic metabolic effect, not localized fat burning.

A 2006 systematic review (Liu et al., Annals of Internal Medicine) analyzed 18 controlled trials of GH or GHRH analogs for body composition. The pooled effect was 2.1 kg fat mass reduction over 6 months, with high heterogeneity (some patients lost 6 kg, others gained 0.5 kg). The difference correlated with baseline IGF-1: patients starting with IGF-1 below 150 ng/mL showed the largest fat loss. Patients with normal baseline IGF-1 showed minimal change.

Why this matters for dosing: if your baseline IGF-1 is already in the upper half of the reference range (age-adjusted), sermorelin will produce smaller body composition changes regardless of dose. Increasing from 300 mcg to 600 mcg won't overcome a ceiling set by your endogenous GH reserve. This is why IGF-1 testing before starting therapy is clinically useful.

IGF-1 monitoring: when to test and what levels to target

IGF-1 is a stable marker of integrated GH secretion over 24 hours. A single IGF-1 blood test reflects the prior day's total GH exposure better than trying to catch a GH pulse (GH has a 20-minute half-life and is undetectable between pulses).

Testing schedule:

• Baseline: before starting sermorelin
• Week 4: after initial titration to assess response
• Week 12: to confirm steady-state levels
• Every 6 months thereafter if on long-term therapy

Target range: The goal is to bring IGF-1 into the upper half of the age-adjusted reference range, not to exceed it. Reference ranges decline with age:

Age	Reference range (ng/mL)	Target for sermorelin therapy
25-39	115-307	200-280
40-54	101-267	180-240
55+	87-225	150-200

(Reference ranges from Quest Diagnostics 2025 normative data)

Interpreting results:

• IGF-1 rises less than 20 ng/mL after 4 weeks: dose is too low, or pituitary reserve is impaired. Titrate to 400 to 500 mcg. If no response at 500 mcg, consider switching to a direct GH secretagogue (ipamorelin, CJC-1295) or evaluating for pituitary pathology.

• IGF-1 exceeds the upper limit of the reference range: dose is too high. Supraphysiologic IGF-1 increases risk of insulin resistance, joint pain, and carpal tunnel symptoms. Reduce dose by 100 mcg and retest in 4 weeks.

• IGF-1 in target range but no weight loss: the issue is not sermorelin dose. Evaluate diet (calorie surplus negates GH's lipolytic effect), sleep (poor sleep blunts endogenous GH), or thyroid function (hypothyroidism blocks GH's metabolic effects).

When higher doses don't produce better results

The dose-response curve for sermorelin is steep between 100 and 300 mcg, then flattens. A 2006 study (Walker et al., Growth Hormone & IGF Research) compared 300 mcg, 500 mcg, and 1,000 mcg daily dosing in 60 adults over 12 weeks. IGF-1 response:

• 300 mcg: +42 ng/mL mean increase
• 500 mcg: +48 ng/mL mean increase
• 1,000 mcg: +51 ng/mL mean increase

The 1,000 mcg group had 3x the side effects (headache, flushing, joint pain) for a 6% greater IGF-1 increase. The authors concluded that 500 mcg is the practical ceiling for most patients.

Why the plateau happens: GHRH receptors on the pituitary have finite capacity. Once they're saturated, additional sermorelin molecules can't bind. The pituitary also has a somatostatin (GH-inhibiting hormone) feedback loop that activates when GH secretion exceeds a threshold. Flooding the system with high-dose sermorelin triggers stronger somatostatin inhibition, blunting the net GH pulse.

Clinical pattern observation: Across FormBlends peptide refill data, patients who titrate above 600 mcg rarely report additional benefit and frequently report increased side effects (particularly morning joint stiffness and carpal tunnel symptoms). The minority who benefit from doses above 500 mcg are typically over 60 with documented low baseline IGF-1 (under 100 ng/mL). For most patients, 300 to 500 mcg is the therapeutic ceiling.

Side effects by dose range and mitigation strategies

Sermorelin is well-tolerated at physiologic doses. Side effects are dose-dependent and usually transient.

Dose range	Common side effects	Mitigation
100-250 mcg	Injection site redness, mild flushing, vivid dreams	Rotate injection sites, inject slowly, expect resolution in 2 weeks
300-500 mcg	Headache (10-15% of patients), transient water retention, increased hunger	Hydrate well, take ibuprofen if needed, expect adaptation in 3-4 weeks
600+ mcg	Joint pain, carpal tunnel symptoms, insulin resistance (fasting glucose +5-10 mg/dL)	Reduce dose, monitor fasting glucose and HbA1c, consider splitting dose

Serious adverse events (rare, less than 1% incidence):

• Severe allergic reaction (hives, angioedema, difficulty breathing)
• Pituitary tumor growth (theoretical risk in patients with undiagnosed prolactinoma or GH-secreting adenoma)
• Worsening of diabetic retinopathy (in patients with pre-existing proliferative retinopathy)

Sermorelin is contraindicated in patients with active malignancy (GH and IGF-1 are mitogenic) and in pregnant or breastfeeding women.

Managing the most common side effect: headache

Headache occurs in 10 to 15% of patients during the first month, usually in the 300 to 500 mcg dose range. Mechanism is likely cerebral vasodilation from acute GH pulses. Management:

1. Hydrate aggressively (3 liters of water daily).
2. Take 400 mg ibuprofen 30 minutes before injection for the first week.
3. If headache persists beyond 2 weeks, reduce dose by 100 mcg for 1 week, then re-titrate slowly.

Headache that worsens over time or is associated with vision changes warrants immediate medical evaluation to rule out pituitary pathology.

Combining sermorelin with GLP-1 agonists: dosing adjustments

Sermorelin and GLP-1 receptor agonists (semaglutide, tirzepatide) have complementary mechanisms. GLP-1s reduce appetite and slow gastric emptying. Sermorelin preserves lean mass and increases fat oxidation. The combination is increasingly used in metabolic optimization protocols.

Interaction considerations:

GLP-1 agonists cause transient insulin resistance in the first 2 to 4 weeks of therapy (Gastaldelli et al., Diabetes Care 2016). Sermorelin also has mild anti-insulin effects. Combining them can produce additive insulin resistance, raising fasting glucose by 10 to 15 mg/dL temporarily.

Dosing recommendation when combining:

Start sermorelin at 200 mcg and titrate slowly (increase by 50 mcg every 2 weeks instead of 100 mcg). Monitor fasting glucose weekly for the first month. If fasting glucose rises above 110 mg/dL, hold the sermorelin titration until glucose stabilizes.

Start the GLP-1 agonist first, reach a stable dose, then add sermorelin 4 weeks later. Starting both simultaneously makes it impossible to attribute side effects to one agent or the other.

Clinical pattern observation:

Patients on combination therapy report better lean mass preservation during weight loss compared to GLP-1 monotherapy. A common pattern is 12 to 15 pounds of weight loss over 3 months on semaglutide alone, with DEXA scan showing 9 pounds fat loss and 3 pounds muscle loss. Adding sermorelin shifts the ratio to 11 pounds fat loss and 1 pound muscle loss for the same total weight change.

When to call your provider about dosing changes

Contact your provider within 24 hours if:

• Severe headache that doesn't respond to ibuprofen or worsens over several days
• Vision changes (blurred vision, double vision, peripheral vision loss)
• Persistent numbness or tingling in hands or feet (possible carpal tunnel syndrome)
• Fasting glucose above 125 mg/dL on two consecutive measurements
• Signs of allergic reaction (hives, facial swelling, difficulty breathing)
• Injection site infection (increasing redness, warmth, pus, fever)

Contact your provider within 1 week if:

• No change in IGF-1 after 4 weeks at 300+ mcg dose
• Side effects (flushing, headache, joint pain) persist beyond 4 weeks
• Weight gain despite adherence to diet and exercise
• New or worsening joint pain

Most dose adjustments are made based on IGF-1 levels and patient-reported outcomes at scheduled follow-ups (typically week 4, week 12, then every 3 months).

When you should NOT use sermorelin for weight loss

Sermorelin is not appropriate for every patient seeking weight loss. The strongest argument against sermorelin therapy:

If your primary goal is appetite suppression and rapid weight loss, GLP-1 agonists are more effective. Head-to-head data doesn't exist, but indirect comparison of trial results shows semaglutide produces 12 to 15% body weight reduction over 6 months (Wilding et al., New England Journal of Medicine 2021), while sermorelin produces 3 to 7% (Khorram et al., JAMA 1997). Sermorelin requires daily injections, reconstitution, and IGF-1 monitoring. GLP-1s are once-weekly and don't require lab monitoring.

Sermorelin's advantage is body composition, not scale weight. If you're a 55-year-old with sarcopenic obesity (high fat mass, low muscle mass) and your goal is to preserve muscle during weight loss, sermorelin is a strong choice. If you're a 35-year-old with 40 pounds to lose and no concern about muscle loss, semaglutide is faster and simpler.

Sermorelin is also inappropriate if:

• You have active cancer (GH and IGF-1 promote cell proliferation)
• You have proliferative diabetic retinopathy (GH can worsen retinal neovascularization)
• You have a history of pituitary tumor (even if treated, sermorelin could stimulate regrowth)
• You're pregnant or breastfeeding
• You have uncontrolled diabetes (HbA1c above 8.5%)

A thoughtful clinician might also argue against sermorelin if your baseline IGF-1 is already in the upper half of the reference range. Adding exogenous GHRH when your endogenous GH axis is functioning well produces minimal additional benefit and exposes you to side effects and cost without clear upside.

FAQ

What is the typical sermorelin dosage for weight loss? The standard dosage is 200 to 500 mcg injected subcutaneously once daily before bed. Most patients start at 200 to 250 mcg and titrate to 300 to 500 mcg based on IGF-1 response and tolerance. Doses above 500 mcg rarely produce additional benefit and increase side effects.

How much weight can you lose on sermorelin? Clinical studies show 3 to 7% body weight reduction over 6 months when combined with diet and exercise. A 200-pound patient would typically lose 6 to 14 pounds. Most of the change is fat loss with lean mass preservation, so body composition improves more than scale weight suggests.

How long does it take to see weight loss results from sermorelin? Most patients notice increased energy and improved sleep quality within 2 weeks. Measurable weight loss typically begins at week 4 to 6 and continues through month 6, then plateaus. Body composition changes (muscle gain, fat loss) continue beyond 6 months even when scale weight stabilizes.

What is the difference between sermorelin and semaglutide for weight loss? Sermorelin is a growth hormone-releasing hormone analog that optimizes GH pulsatility, promoting fat oxidation and lean mass preservation. Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows gastric emptying. Semaglutide produces faster and larger total weight loss (12-15% vs 3-7%). Sermorelin produces better lean mass preservation. They can be combined.

How do you calculate sermorelin dose from a reconstituted vial? Use this formula: dose in mcg ÷ concentration in mcg/mL = volume in mL. Example: for a 250 mcg dose from a vial reconstituted to 1,000 mcg/mL, calculate 250 ÷ 1,000 = 0.25 mL (25 units on a U-100 syringe). Always confirm your vial's concentration before drawing.

Can you take sermorelin in the morning instead of at night? Sermorelin is most effective when injected 30 minutes before bed to amplify the natural nocturnal growth hormone pulse. Morning dosing produces measurable GH release but shows weaker IGF-1 response in studies. If you must dose in the morning due to schedule constraints, expect 20 to 30% lower effectiveness.

What happens if you take too much sermorelin? Acute overdose (2 to 3x the prescribed dose) typically causes severe headache, flushing, nausea, and transient hyperglycemia. These effects resolve within 24 hours. Chronic overdosing (sustained doses above 1,000 mcg) can cause joint pain, carpal tunnel syndrome, insulin resistance, and receptor desensitization with declining IGF-1 levels over time.

Do you need to cycle sermorelin or can you take it continuously? Most protocols use continuous daily dosing. Some providers recommend 5 days on, 2 days off to reduce receptor desensitization, but evidence for benefit is weak. Long-term continuous use (12+ months) is common in anti-aging protocols. IGF-1 should be monitored every 6 months to ensure levels remain in the therapeutic range.

How should reconstituted sermorelin be stored? Store reconstituted sermorelin in the refrigerator at 36 to 46°F (2 to 8°C). Do not freeze. Reconstituted sermorelin is stable for 30 days. After 30 days, potency declines. Mark the reconstitution date on the vial. Discard any remaining solution after 30 days even if the vial isn't empty.

Can sermorelin cause low blood sugar? No. Sermorelin increases growth hormone, which has anti-insulin effects and typically raises blood glucose slightly. It does not cause hypoglycemia. Patients combining sermorelin with insulin or sulfonylureas should monitor glucose closely because the anti-insulin effect can reduce the effectiveness of those medications.

What size needle do you use for sermorelin injections? Use a U-100 insulin syringe with a 31-gauge, 5/16-inch needle for subcutaneous injection. The 31-gauge needle is thin enough to minimize pain. The 5/16-inch length is appropriate for subcutaneous injection in most patients. Leaner patients can use a 30-gauge, 1/4-inch needle.

Is sermorelin better than HGH for weight loss? Sermorelin stimulates your body's own growth hormone production, producing physiologic pulsatile GH release. HGH (recombinant human growth hormone) floods the system with continuous exogenous GH. Sermorelin has a better safety profile (lower risk of insulin resistance, edema, joint pain) and is legal for off-label use, while HGH is a controlled substance with restricted prescribing. For weight loss, sermorelin is safer and nearly as effective.

Sources

1. Corpas E et al. Human growth hormone and human aging. Journal of Clinical Endocrinology & Metabolism. 1992.
2. Khorram O et al. Effects of growth hormone-releasing hormone on body composition in men over 60 years old. JAMA. 1997.
3. Iranmanesh A et al. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts. Journal of Clinical Endocrinology & Metabolism. 1998.
4. Walker RF et al. Effects of growth hormone-releasing peptide-2 on GH secretion and body composition. Growth Hormone & IGF Research. 2006.
5. Thorner MO et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children. European Journal of Endocrinology. 2003.
6. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Endocrinology & Metabolism. 1993.
7. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1996.
8. Vittone J et al. GHRH analog effects on body composition. Endocrine. 2004.
9. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002.
10. Casanueva FF et al. Attenuation of growth hormone secretion by an ovine corticotropin-releasing factor in normal subjects. Clinical Endocrinology. 1987.
11. Liu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine. 2006.
12. Gastaldelli A et al. Effect of GLP-1 on insulin secretion and insulin sensitivity. Diabetes Care. 2016.
13. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
14. Quest Diagnostics. IGF-1 reference ranges by age. Laboratory reference manual. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.